Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 6/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30097054 | 0.81 | L3MBTL1 (0.38) | L3MBTL1HTR2B | |
| SCHEMBL30097053 | 0.80 | MAOA (0.36) | L3MBTL1RAB9A | |
| SCHEMBL23705922 | 0.79 | HTR2B (0.45) | HTR2B | |
| SCHEMBL17017128 | 0.74 | L3MBTL1 (0.46) | L3MBTL1ACHETGFBR1RAB9A | |
| SCHEMBL30097048 | 0.72 | TP53 (0.41) | — | |
| SCHEMBL17017926 | 0.71 | L3MBTL1 (0.46) | L3MBTL1ACHERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL30097047 | 0.70 | FAAH (0.44) | L3MBTL1TGFBR1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL22366449 | 0.69 | L3MBTL1 (0.47) | L3MBTL1ACHERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL30097018 | 0.69 | ATM (0.44) | L3MBTL1TGFBR1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL30097049 | 0.69 | MAPKAPK2 (0.42) | L3MBTL1TGFBR1RAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4096667-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |